{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=19", "query": { "intervention": "Continuous infusion", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 2658, "total_pages": 266, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+infusion&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T02:16:57.531Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02782546", "title": "Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Graft cell infusion", "type": "PROCEDURE" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "CIML NK cell infusion", "type": "PROCEDURE" }, { "name": "ALT-803", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-01-30", "completion_date": "2028-02-13", "has_results": true, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782546" }, { "nct_id": "NCT01868022", "title": "Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3052230", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2013-10-09", "completion_date": "2017-10-24", "has_results": true, "last_update_posted_date": "2019-08-19", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 10, "location_summary": "Duarte, California • Sacramento, California • Chicago, Illinois + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01868022" }, { "nct_id": "NCT01018069", "title": "AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "AEG35156", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aegera Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2009-11", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2011-07-13", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 6, "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Valhalla", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01018069" }, { "nct_id": "NCT06526819", "title": "SMP-3124LP in Adults With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "SMP3124LP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-08-14", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06526819" }, { "nct_id": "NCT01226927", "title": "The Efficacy of Automated Intermittent Boluses for Continuous Femoral Nerve Block: a Prospective, Randomized Comparison to Continuous Infusions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Arthroplasty, Replacement, Knee", "Nerve Block" ], "interventions": [ { "name": "Automated intermittent bolus", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 45, "start_date": "2009-04", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2010-10-22", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01226927" }, { "nct_id": "NCT06268431", "title": "Oxytocin Rest to Reduce Cesarean Delivery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prolonged Labor", "Failed Induction", "Labor Dystocia" ], "interventions": [ { "name": "Oxytocin rest", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Christiana Care Health Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 350, "start_date": "2024-03-19", "completion_date": "2026-03-15", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 1, "location_summary": "Newark, Delaware", "locations": [ { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT06268431" }, { "nct_id": "NCT03994731", "title": "Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Gout" ], "interventions": [ { "name": "Pegloticase", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "folic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "gout flare prophylaxis regimen", "type": "DRUG" }, { "name": "fexofenadine", "type": "DRUG" }, { "name": "acetaminophen", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2019-06-13", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03994731" }, { "nct_id": "NCT06506565", "title": "Low-Dose Ketamine Infusion During Burn Wound Care", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Burn", "Pain", "Dissociation", "Opioid" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "0.9% NaCl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2024-07-08", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-12-13", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06506565" }, { "nct_id": "NCT04846829", "title": "Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "intermittent theta burst stimulation", "type": "DEVICE" }, { "name": "intravenous citalopram hydrochloride (CIT)", "type": "DRUG" }, { "name": "continuous theta burst stimulation", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "21 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2017-04-24", "completion_date": "2028-04-24", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04846829" }, { "nct_id": "NCT01378377", "title": "Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Pimasertib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2011-05-27", "completion_date": "2012-02-23", "has_results": true, "last_update_posted_date": "2018-07-30", "last_synced_at": "2026-10-21T02:16:57.531Z", "location_count": 3, "location_summary": "Los Angeles, California • Rockland, Massachusetts • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rockland", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01378377" } ] }